Skip to main content
Premium Trial:

Request an Annual Quote

Thallion Sells 80-Percent Stake in Caprion Proteomics to Healthcare Investor Great Point

NEW YORK (GenomeWeb News) — Thallion Pharmaceuticals said today it has sold 80 percent of its stake in its Caprion Proteomics business to a company owned by Great Point Partners, while Thallion will retain the remaining 20 percent of the company.
 
The deal will leave the new company, which will be called Caprion Proteomics, owning “substantially all" of Thallion’s proteomics assets, including the CellCarta platform. It will adopt $22.2 million in Thallion’s long-term debt obligations.
 
Caprion also will issue $4.1 million in secured subordinated notes to Thallion at an annual interest rate of 9.5 percent.
 
In a statement, Thallion CEO Lloyd Segal said the deal fits the company’s plan to slash debt and to “focus our resources on the development of our clinical product candidates.”
 
The deal grants Thallion 100 percent of all royalty payments and 50 percent of all milestone payments coming from proteomics licensing revenue, Thallion said.
 
Thallion, which specializes in oncology and infectious diseases, also said it collected rights to an undisclosed target candidate derived from CellCarta for preclinical and clinical development, and preferred services involved in biomarker development.
 
Great Point also is obligated to make an undisclosed “material investment” in Caprion Proteomics for working capital purposes, and Caprion will take on 35 of Thallion’s current proteomics employees.
 
Caprion Proteomics President Martin LeBlanc will take the helm as CEO of the new company.
 
Caprion Proteomics is a remnant of a company once called Caprion Pharmaceuticals, which earlier this year merged with Ecopia BioSciences to form Thallion. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more